Invention Grant
- Patent Title: Substituted imidazole as bombesin receptor subtype-3 modulators
- Patent Title (中): 取代咪唑作为铃蟾肽受体亚型-3调节剂
-
Application No.: US12311487Application Date: 2007-10-16
-
Publication No.: US08193228B2Publication Date: 2012-06-05
- Inventor: David Chen , Christopher L. Franklin , Peter R. Guzzo , Linus S. Lin , Michael M. C. Lo , Ravi P. Nargund , Iyassu K. Sebhat
- Applicant: David Chen , Christopher L. Franklin , Peter R. Guzzo , Linus S. Lin , Michael M. C. Lo , Ravi P. Nargund , Iyassu K. Sebhat
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Baerbel R. Brown; John C. Todaro
- International Application: PCT/US2007/022087 WO 20071016
- International Announcement: WO2008/051406 WO 20080502
- Main IPC: A61K31/4178
- IPC: A61K31/4178 ; A61K31/4164 ; C07D471/04 ; C07D401/10 ; C07D403/10 ; C07D233/64

Abstract:
Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.
Public/Granted literature
- US20100022598A1 Substituted inmidazoles as bombesin receptor subtype-3 modulators Public/Granted day:2010-01-28
Information query
IPC分类: